Leitat
At Leitat, we are committed to the future by creating high-impact biotechnology companies such as Gene Vector, Medtech Barcelona and Amira Therapeutics, generating economic, social and technological value. Find out more!
Leitat
At Leitat, we are committed to the future by creating high-impact biotechnology companies such as Gene Vector, Medtech Barcelona and Amira Therapeutics, generating economic, social and technological value. Find out more!
Founded in 2021, Gene Vector Barcelona is a subsidiary of the Leitat Technological Center organization, which was born as an SPC to comply with all the regulatory and legal requirements set by the Spanish Medicines Agency (AEMPS) to manufacture and export the viral vector used for the second-generation CAR-T Therapy (CAR-T ARI-00001).
Its main objective is to contribute to greater equity in accessibility to the most innovative gene therapies for patients around the world.
Gene Vector Barcelona’s lentiviral production is the result of the technological transfer from the Hospital Clinic de Barcelona and therefore acts as the necessary bridge between the hospital and any potential user abroad.
Gene Vector Barcelona has obtained the Manufacturing and Import Authorization (MIA) from the AEMPS, which allows the product to be distributed throughout Europe and sets the standards for its approval abroad.
Amira Therapeutics emerged in 2023 as a spin-off of Leitat and is dedicated to the development of new drugs to fight childhood cancer. Its pipeline is composed of two compounds that emerged from the Drug Discovery process which are currently advancing through preclinical development, necessary for human trials.
Amira is a name inspired by the love we feel for our children, our princes and princesses (Amira in various cultures), and how cancer becomes a life-changing event. We exist to dramatically change the perspectives of families who receive the devastating news of a diagnosis of cancer or other life-threatening diseases.
Amira Therapeutics’ goal is to reach patients by developing innovative compounds and collaborating with industry leaders while implementing a rapid development strategy. This is exemplified by their partnership with the Vall d’Hebron University Hospital Foundation (VHIR), with whom they have worked together since the beginning of the project, developing a family of patents that protects the compound and its indication in different territories, including Europe, the USA and Japan. Its most advanced compound, AMI463, has received several distinctions from regulatory authorities in Europe and the United States.
Currently, Amira is associated with the MGC Foundation, with whom it shares the vision of redefining current treatments for children by developing targeted therapies and reducing the use of conventional cytotoxic chemotherapy.
MedTech Innovation on Advanced Medicine (MedTech Barcelona) is a biotechnology company focused on developing innovative solutions for the healthcare and pharmaceutical sectors. Fully owned by Leitat, MedTech Barcelona acts as a marketing platform for the organization’s new projects.
Phone. (+34) 937 882 300
